v3.25.4
Segment Information - Schedule of Significant Revenue and Expense Categories of the Company’s Single Operating Segment (Details) - USD ($)
3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Dec. 31, 2024
Sep. 30, 2025
Sep. 30, 2024
Jun. 30, 2024
Operating expenses:            
Clinical trial related service fee $ 4,125,000 $ 2,801,000   $ 10,125,000 $ 6,301,000  
Consulting fee 17,228 25,000   67,228 75,000  
Stock-based compensation 152,421 $ 432,256 470,614 $ 1,194,653
Salary expense 132,054 133,811   392,861 385,360  
Professional fee 184,791 293,934   945,318 645,238  
Insurance expense 86,690 88,456   251,383 263,443  
Other general and administrative fee 102,965 34,536   197,071 125,673  
Loss before income tax 4,801,149 3,376,737 4,426,964 12,449,475 7,795,714 7,310,098
Income tax expense $ 63 863 1,625 $ 1,625
Net loss $ 4,801,149 $ 3,376,737   $ 12,450,338 $ 7,797,339